Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Schistosoma mansoni | hypothetical protein | 0.0037 | 1 | 0.5 |
Plasmodium falciparum | ataxin-2 like protein, putative | 0.0026 | 0 | 0.5 |
Leishmania major | hypothetical protein, conserved | 0.0026 | 0 | 0.5 |
Entamoeba histolytica | hypothetical protein | 0.0037 | 1 | 0.5 |
Plasmodium falciparum | ataxin-2 like protein, putative | 0.0026 | 0 | 0.5 |
Schistosoma mansoni | transcription factor LCR-F1 | 0.0037 | 1 | 0.5 |
Entamoeba histolytica | hypothetical protein | 0.0037 | 1 | 0.5 |
Entamoeba histolytica | hypothetical protein | 0.0037 | 1 | 0.5 |
Echinococcus multilocularis | Basic leucine zipper (bZIP) transcription | 0.0037 | 1 | 0.5 |
Trypanosoma cruzi | PAB1-binding protein , putative | 0.0026 | 0 | 0.5 |
Echinococcus granulosus | Basic leucine zipper bZIP transcription | 0.0037 | 1 | 0.5 |
Entamoeba histolytica | hypothetical protein | 0.0037 | 1 | 0.5 |
Trypanosoma cruzi | PAB1-binding protein , putative | 0.0026 | 0 | 0.5 |
Toxoplasma gondii | LsmAD domain-containing protein | 0.0026 | 0 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0026 | 0 | 0.5 |
Plasmodium vivax | ataxin-2 like protein, putative | 0.0026 | 0 | 0.5 |
Trypanosoma brucei | PAB1-binding protein , putative | 0.0026 | 0 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Potency (functional) | 11.6891 uM | PUBCHEM_BIOASSAY: Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 48 hour incubation. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID488752, AID488774, AID504848, AID504850] | ChEMBL. | No reference |
Potency (binding) | = 28.1838 um | PUBCHEM_BIOASSAY: qHTS Assay for Identification of Novel General Anesthetics. In this assay, a GABAergic mimetic model system, apoferritin and a profluorescent 1-aminoanthracene ligand (1-AMA), was used to construct a competitive binding assay for identification of novel general anesthetics (Class of assay: confirmatory) [Related pubchem assays: 2385 (Probe Development Summary for Identification of Novel General Anesthetics), 2323 (Validation apoferritin assay run on SigmaAldrich LOPAC1280 collection)] | ChEMBL. | No reference |
Potency (functional) | 39.8107 uM | PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors of GCN5L2. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID504398] | ChEMBL. | No reference |
Potency (functional) | 44.6684 uM | PubChem BioAssay. qHTS for Inhibitors of ATXN expression. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 79.4328 uM | PUBCHEM_BIOASSAY: HTS for Inhibitors of HP1-beta Chromodomain Interactions with Methylated Histone Tails. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID488962] | ChEMBL. | No reference |
Potency (functional) | = 89.1251 um | PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors of Bacillus subtilis Sfp phosphopantetheinyl transferase (PPTase). (Class of assay: confirmatory) | ChEMBL. | No reference |
Species name | Source | Reference | Is orphan |
---|---|---|---|
Plasmodium falciparum | ChEMBL23 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.